MedTrace Logo

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

NCT00645918 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2800

Last updated 2011-06-16

No results posted yet for this study

Summary

The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.

Conditions

  • Coronary Arteriosclerosis
  • Acute Coronary Syndrome

Interventions

DRUG

clopidogrel

oral, 75 mg daily for 6 months starting on day of randomization

DRUG

placebo

oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization

DRUG

clopidogrel

oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization

Sponsors & Collaborators

  • Accumetrics, Inc.

    lead INDUSTRY

Principal Investigators

  • Matthew J Price, M.D. · Scripps Advanced Clnical Trials

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00645918 on ClinicalTrials.gov